CervoMed Inc

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November:

CervoMed to Participate in Upcoming Investor Conferences

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the eighth International Lewy Body Dementia Conference (ILBDC) taking place on January 29-31, 2025 in Amsterdam, the Netherlands. “As we await topline results from the RewinD-LB Phase 2b trial in DLB, we are extremely encouraged by the scientific community's interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to Lewy Body Dementia,” said John Alam, MD, Chief Executive Officer of CervoMed.

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications” Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will present virtually at the Emerging Growth Conference.

CervoMed to Participate in the Emerging Growth Conference

BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Adams Resources & Energy

Arrowhead Pharmaceuticals

AtriCure

Forward Air

Matthews International

Medifast

Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.

Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB). “Drug development for the major dementias over the past decade has progressively focused on earlier stages of disease.

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition.

CervoMed to Appoint William Elder as Chief Financial Officer

- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024-

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Results from the phase 2b RewinD-LB study, using neflamapimod for the treatment of patients with Dementia With Lewy bodies, are expected in the 2nd half of 2024. The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033. If targeting of p38 alpha protein to inhibit synaptic dysfunction works for DLB, then potential to apply the same mechanism of action towards Alzheimer's Disease, Frontotemporal dementia, and other neurological disorders.

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.

CervoMed to Participate in the BIO CEO and Investor Conference

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board.

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.

CervoMed to Participate in the Emerging Growth Conference 67

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024.

CervoMed to Participate in the Emerging Growth Conference 66

Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ("CRVO") CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON , Nov. 13, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights. "This has been an active and exciting quarter as we completed our merger and launch of CervoMed, while also enrolling the first patient in our RewinD-LB Phase 2b study of neflamapimod for dementia with Lewy bodies (DLB)," said John Alam, MD, Chief Executive Officer of CervoMed.

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power  to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo  New data included in the presentation show that in patients without Alzheimer's-related co-pathology, neflamapimod treatment demonstrates significant reduction vs.

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

News for CervoMed Inc Stock (CRVO)